{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:35:41Z","timestamp":1770788141422,"version":"3.50.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["GA101072861"],"award-info":[{"award-number":["GA101072861"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["13876"],"award-info":[{"award-number":["13876"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Just Transition Fund","award":["Just Transition Fund"],"award-info":[{"award-number":["Just Transition Fund"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07701-5","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:44:46Z","timestamp":1768538686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Jimena \u00c1lvarez","family":"Freile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Rockstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rianne","family":"Kloosterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena Gonz\u00e1lez","family":"Corrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nienke","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm Jan","family":"Lourens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Frittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Dennebos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nienke A. M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Airies","family":"Setroikomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Requesens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nienke","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysenur","family":"\u00d6ner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahez","family":"Gareb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-7376","authenticated-orcid":false,"given":"Edwin","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"9","key":"7701_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134\u201342.","journal-title":"Blood"},{"issue":"3","key":"7701_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ajh.27205","volume":"99","author":"VA Vardell","year":"2024","unstructured":"Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM. T-cell prolymphocytic leukemia: epidemiology and survival trends in the era of novel treatments. Am J Hematol. 2024;99(3):494\u20136.","journal-title":"Am J Hematol"},{"issue":"4","key":"7701_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","volume":"9","author":"NC Maciocia","year":"2024","unstructured":"Maciocia NC, Wade BG, Maciocia PM. CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? Blood Adv. 2024;9(4):913\u201323.","journal-title":"Blood Adv"},{"issue":"11","key":"7701_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cam4.7375","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy. Cancer Med. 2024;13(11):1\u201316.","journal-title":"Cancer Med"},{"issue":"May","key":"7701_CR5","first-page":"1","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S, et al. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Front Immunol. 2023;14(May):1\u201313.","journal-title":"Front Immunol"},{"issue":"January","key":"7701_CR6","first-page":"1","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, An Y, Sun R, Zhang X, Guo S, Gao X, et al. The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis. Front Oncol. 2024;14(January):1\u201310.","journal-title":"Front Oncol"},{"issue":"12","key":"7701_CR7","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang J, Li J, Qiu L, Zhang J, Lu Y, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023;98(12):1898\u2013908.","journal-title":"Am J Hematol"},{"issue":"11","key":"7701_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32(11):995\u20131007.","journal-title":"Cell Res"},{"issue":"December","key":"7701_CR9","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat Med. 2024;30(December):3687\u201396.","journal-title":"Nat Med"},{"issue":"1","key":"7701_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00822-w","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 2023;13(1):1\u201310.","journal-title":"Blood Cancer J"},{"issue":"6","key":"7701_CR11","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.ymthe.2024.09.006","volume":"33","author":"L Zhao","year":"2025","unstructured":"Zhao L, Li C, Zuo S, Han Y, Deng B, Ling Z, et al. Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: A phase I trial. Mol Ther. 2025;33(6):2753\u201367.","journal-title":"Mol Ther"},{"issue":"23","key":"7701_CR12","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1182\/bloodadvances.2024012982","volume":"8","author":"\u00c1 Urbano-Ispizua","year":"2024","unstructured":"Urbano-Ispizua \u00c1, Shah NN, Kekre N. Point-of-care CAR T manufacturing solutions: can 1 model fit all? Blood Adv. 2024;8(23):6133\u20136.","journal-title":"Blood Adv"},{"issue":"September","key":"7701_CR13","first-page":"1","volume":"2","author":"M Shah","year":"2023","unstructured":"Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E. Promises and challenges of a decentralized CAR T-cell manufacturing model. Front Transpl. 2023;2(September):1\u20139.","journal-title":"Front Transpl"},{"issue":"3","key":"7701_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"2","key":"7701_CR15","doi-asserted-by":"publisher","first-page":"200988","DOI":"10.1016\/j.omton.2025.200988","volume":"33","author":"N Visser","year":"2025","unstructured":"Visser N, Gonz\u00e1lez-Corrales M, \u00c1lvarez-Freile J, Pruis MG, Rockstein L, Lourens HJ, et al. K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies. Mol Ther Oncol. 2025;33(2):200988.","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"7701_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","volume":"27","author":"D Gomes-Silva","year":"2019","unstructured":"Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, et al. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Ther. 2019;27(1):272\u201380.","journal-title":"Mol Ther"},{"issue":"9","key":"7701_CR17","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Jessica M, Eckardt K, et al. An \u2018off-the-shelf\u2019 fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970\u201383.","journal-title":"Leukemia"},{"issue":"10","key":"7701_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-Edited CAR7 T cells for relapsed T-Cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"1","key":"7701_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol Ther. 2023;31(1):24\u201334.","journal-title":"Mol Ther"},{"issue":"8","key":"7701_CR20","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","volume":"37","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, et al. Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 2023;37(8):1660\u201370.","journal-title":"Leukemia"},{"issue":"June","key":"7701_CR21","first-page":"1","volume":"14","author":"V Moradi","year":"2024","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, Omidkhoda A, Ahmadbeigi N. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review. Front Oncol. 2024;14(June):1\u201318.","journal-title":"Front Oncol"},{"key":"7701_CR22","doi-asserted-by":"crossref","unstructured":"June CH, Fraietta JA, Singh N. Regulatory considerations for genome-edited T-cell therapies. 2025;12(March 2022):1132\u20135.","DOI":"10.1158\/2326-6066.CIR-24-0482"},{"issue":"4","key":"7701_CR23","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140(4):321\u201334.","journal-title":"Blood"},{"issue":"13","key":"7701_CR24","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/bloodadvances.2022008402","volume":"7","author":"W Wei","year":"2023","unstructured":"Wei W, Ma H, Yang D, Sun B, Tang J, Zhu Y, et al. SECTM1-based CAR T cells enriched with CD7-low\/negative subsets exhibit efficacy in CD7-positive malignancies. Blood Adv. 2023;7(13):2941\u201351.","journal-title":"Blood Adv"},{"issue":"5","key":"7701_CR25","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1074\/jbc.275.5.3431","volume":"275","author":"SD Lyman","year":"2000","unstructured":"Lyman SD, Escobar S, Rousseau AM, Armstrong A, Fanslow WC. Identification of CD7 as a cognate of the human K12 (SECTM1) protein. J Biol Chem. 2000;275(5):3431\u20137.","journal-title":"J Biol Chem"},{"key":"7701_CR26","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta M, Carmona SJ, UCell. Robust and scalable single-cell gene signature scoring. Comput Struct Biotechnol J. 2021;19:3796\u20138.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"7701_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213.","journal-title":"Blood Cancer J"},{"key":"7701_CR28","doi-asserted-by":"crossref","unstructured":"Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN et al. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med. 2023;15(690).","DOI":"10.1126\/scitranslmed.abk1900"},{"key":"7701_CR29","unstructured":"FDA. Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products-Guidance for Industry. 2024."},{"key":"7701_CR30","unstructured":"EMA\/CAT\/123573\/. 2024. Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. 2025."},{"issue":"11","key":"7701_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-007803","volume":"11","author":"SY Lee","year":"2023","unstructured":"Lee SY, Lee DH, Sun W, Cervantes-Contreras F, Basom RS, Wu F, et al. CD8\u2009+\u2009chimeric antigen receptor T cells manufactured in absence of CD4\u2009+\u2009cells exhibit hypofunctional phenotype. J Immunother Cancer. 2023;11(11):1\u201314.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"7701_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/1523-1747.ep12371791","volume":"102","author":"M Moll","year":"1994","unstructured":"Moll M, Reinhold U, Kukel S, Abken H, M\u00fcller R, Oltermann I, et al. CD7-negative helper T cells accumulate in inflammatory skin lesions. J Invest Dermatol. 1994;102(3):328\u201332.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"7701_CR33","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1067\/mjd.2001.110900","volume":"44","author":"G Rappl","year":"2001","unstructured":"Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, et al. CD4\u2009+\u2009CD7\u2009\u2013\u2009T cells compose the dominant T-cell clone in the peripheral blood of patients with S\u00e9zary syndrome. J Am Acad Dermatol. 2001;44(3):456\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"7701_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2567.1996.d01-744.x","volume":"89","author":"U Reinhold","year":"1996","unstructured":"Reinhold U, Liu L, Sesterhenn J, Abken H. CD7-negative T cells represent a separate differentiation pathway in a subset of post-thymic helper T cells. Immunology. 1996;89(3):391\u20136.","journal-title":"Immunology"},{"issue":"2","key":"7701_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/intimm\/5.2.179","volume":"5","author":"RE Ware","year":"1993","unstructured":"Ware RE, Haynes BF. T cell CD7 mRNA expression is regulated by both transcriptional and post-transcriptional mechanisms. Int Immunol. 1993;5(2):179\u201387.","journal-title":"Int Immunol"},{"issue":"1","key":"7701_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2008.03.049","volume":"370","author":"HS Koh","year":"2008","unstructured":"Koh HS, Lee C, Lee KS, Ham CS, Seong RH, Kim SS, et al. CD7 expression and galectin-1-induced apoptosis of immature thymocytes are directly regulated by NF-\u03baB upon T-cell activation. Biochem Biophys Res Commun. 2008;370(1):149\u201353.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"7701_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10059-009-0150-8","volume":"28","author":"HS Koh","year":"2009","unstructured":"Koh HS, Lee C, Lee KS, Park EJ, Seong RH, Hong S, et al. Twist2 regulates CD7 expression and Galectin-1-Induced apoptosis in mature T-Cells. Mol Cells. 2009;28(6):553\u20138.","journal-title":"Mol Cells"},{"issue":"5","key":"7701_CR38","first-page":"840","volume":"16","author":"G Rappl","year":"2002","unstructured":"Rappl G, Abken H, Muche JM, Sterry W, Tilgen W, Andr\u00e9 S, et al. CD4\u2009+\u2009CD7\u2009\u2013\u2009leukemic T cells from patients with S\u00e9zary syndrome are protected from galectin-1-triggered T cell death. Leuk 2002 165. 2002;16(5):840\u20135.","journal-title":"Leuk 2002 165"},{"key":"7701_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-3-15","volume":"3","author":"S R\u00f6hrs","year":"2010","unstructured":"R\u00f6hrs S, Scherr M, Romani J, Zaborski M, Drexler HG, Quentmeier H. CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. J Hematol Oncol. 2010;3:15.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"7701_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09537104.2020.1849602","volume":"32","author":"L Barro","year":"2021","unstructured":"Barro L, Burnouf PA, Chou ML, Nebie O, Wu YW, Chen MS, et al. Human platelet lysates for human cell propagation. Platelets. 2021;32(2):152\u201362.","journal-title":"Platelets"},{"key":"7701_CR41","doi-asserted-by":"crossref","unstructured":"Canestrari E, Steidinger HR, McSwain B, Charlebois SJ, Dann CT. Human platelet lysate media supplement supports lentiviral transduction and expansion of human T lymphocytes while maintaining memory phenotype. J Immunol Res. 2019;2019.","DOI":"10.1155\/2019\/3616120"},{"issue":"1","key":"7701_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0804-9","volume":"7","author":"A Torres Chavez","year":"2019","unstructured":"Torres Chavez A, McKenna MK, Canestrari E, Dann CT, Ramos CA, Lulla P, et al. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019;7(1):1\u201315.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"7701_CR43","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jcyt.2024.03.006","volume":"26","author":"F Mo","year":"2024","unstructured":"Mo F, Tsai CT, Zheng R, Cheng C, Heslop HE, Brenner MK, et al. Human platelet lysate enhances in vivo activity of CAR-V\u03b42 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024;26(8):858\u201368.","journal-title":"Cytotherapy"},{"issue":"17","key":"7701_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21176284","volume":"21","author":"M Ca\u00f1as-Arboleda","year":"2020","unstructured":"Ca\u00f1as-Arboleda M, Beltr\u00e1n K, Medina C, Camacho B, Salguero G. Human platelet lysate supports efficient expansion and stability of wharton\u2019s jelly mesenchymal stromal cells via active uptake and release of soluble regenerative factors. Int J Mol Sci. 2020;21(17):1\u201319.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"7701_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","volume":"26","author":"HW Song","year":"2024","unstructured":"Song HW, Prochazkova M, Shao L, Traynor R, Underwood S, Black M, et al. CAR-T cell expansion platforms yield distinct T cell differentiation States. Cytotherapy. 2024;26(7):757\u201368.","journal-title":"Cytotherapy"},{"issue":"1","key":"7701_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-022-00516-1","volume":"23","author":"S Liu","year":"2022","unstructured":"Liu S, Huang Z, Fan R, Jia J, Deng X, Zou X, et al. Cycling and activated CD8\u2009+\u2009T lymphocytes and their association with disease severity in influenza patients. BMC Immunol. 2022;23(1):1\u20139.","journal-title":"BMC Immunol"},{"issue":"17","key":"7701_CR47","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1089\/088922202320886343","volume":"18","author":"SE Starr","year":"2002","unstructured":"Starr SE, Sarr M, Campbell DE, Wilson CM, Douglas SD. Increased proliferation within T lymphocyte subsets of HIV-infected adolescents. AIDS Res Hum Retroviruses. 2002;18(17):1301\u201310.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"7701_CR48","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/bjh.18863","volume":"202","author":"R Borrill","year":"2023","unstructured":"Borrill R, Poulton K, Kusyk L, Routledge A, Bonney D, Hanasoge-Nataraj R, et al. Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8\u2009+\u2009T-cell expansion, significant cytokine release syndrome and induction of disease remission. Br J Haematol. 2023;202(3):589\u201398.","journal-title":"Br J Haematol"},{"issue":"1","key":"7701_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-31504-z","volume":"13","author":"LL Niborski","year":"2022","unstructured":"Niborski LL, Gueguen P, Ye M, Thiolat A, Ramos RN, Caudana P, et al. CD8\u2009+\u2009T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas. Nat Commun. 2022;13(1):1\u201316.","journal-title":"Nat Commun"},{"issue":"6","key":"7701_CR50","doi-asserted-by":"publisher","first-page":"101053","DOI":"10.1016\/j.xcrm.2023.101053","volume":"4","author":"IY Jung","year":"2023","unstructured":"Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep Med. 2023;4(6):101053.","journal-title":"Cell Rep Med"},{"issue":"12","key":"7701_CR51","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas. Nat Med. 2020;26(12):1878.","journal-title":"Nat Med"},{"issue":"5","key":"7701_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563.","journal-title":"Nat Med"},{"issue":"5","key":"7701_CR53","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney OC, Brakke H, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129(5):2123.","journal-title":"J Clin Invest"},{"issue":"10","key":"7701_CR54","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1073\/pnas.1712107115","volume":"115","author":"L Avery","year":"2018","unstructured":"Avery L, Filderman J, Szymczak-Workman AL, Kane LP. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc Natl Acad Sci U S A. 2018;115(10):2455\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7701_CR55","first-page":"P190","volume":"1","author":"H-B Jie","year":"2013","unstructured":"Jie H-B, Li J, Srivastava R, Ferris RL. TIM-3\u2009+\u2009T cells are not exhausted but activated cells in the tumor microenvironment. J Immunother Cancer 2013 11. 2013;1(1):P190.","journal-title":"J Immunother Cancer 2013 11"},{"issue":"17","key":"7701_CR56","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1042\/BCJ20210425","volume":"478","author":"CM Smith","year":"2021","unstructured":"Smith CM, Li A, Krishnamurthy N, Lemmon MA. Phosphatidylserine binding directly regulates TIM-3 function. Biochem J. 2021;478(17):3331\u201349.","journal-title":"Biochem J"},{"key":"7701_CR57","doi-asserted-by":"crossref","unstructured":"Lee MJ, Yun SJ, Lee B, Jeong E, Yoon G, Kim K et al. Association of TIM-3 expression with glucose metabolism in Jurkat T cells. BMC Immunol. 2020;21(1).","DOI":"10.1186\/s12865-020-00377-6"},{"issue":"10","key":"7701_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1200778","volume":"5","author":"J Li","year":"2016","unstructured":"Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3\u2009+\u2009T cells proliferate avidly except when PD-1 is co-expressed: evidence for intracellular cross talk. Oncoimmunology. 2016;5(10):1\u201313.","journal-title":"Oncoimmunology"},{"issue":"94","key":"7701_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.adg1094","volume":"9","author":"SA Minnie","year":"2024","unstructured":"Minnie SA, Waltner OG, Zhang P, Takahashi S, Nemychenkov NS, Ensbey KS, et al. TIM-3\u2009+\u2009CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. Sci Immunol. 2024;9(94):1\u201337.","journal-title":"Sci Immunol"},{"issue":"2","key":"7701_CR60","doi-asserted-by":"publisher","first-page":"102225","DOI":"10.1016\/j.omtn.2024.102225","volume":"35","author":"H Hu","year":"2024","unstructured":"Hu H, Tang L, Zhao Y, Cheng J, Huang M, You Y, et al. Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies. Mol Ther Nucleic Acids. 2024;35(2):102225.","journal-title":"Mol Ther Nucleic Acids"},{"key":"7701_CR61","doi-asserted-by":"crossref","unstructured":"Wang D, Forman SJ, Brown CE, Car T, Wang D, Aguilar B et al. Glioblastoma-targeted CD4\u2009+\u2009CAR T cells mediate superior antitumor activity. JCI Insight. 2018;3(10).","DOI":"10.1172\/jci.insight.99048"},{"key":"7701_CR62","doi-asserted-by":"crossref","unstructured":"Guerrero-murillo M, Rill-hinarejos A, Trincado JL, Mereu E, Bueno C. Integrative single-cell multi-omics of CD19-CAR Pos and CAR Neg T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Rep Med. 2024;5(11).","DOI":"10.1016\/j.xcrm.2024.101803"},{"issue":"4","key":"7701_CR63","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.19117","volume":"203","author":"E Galli","year":"2023","unstructured":"Galli E, Bellesi S, Pansini I, Di Cesare G, Iacovelli C, Malafronte R, et al. The CD4\/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br J Haematol. 2023;203(4):564\u201370.","journal-title":"Br J Haematol"},{"key":"7701_CR64","doi-asserted-by":"crossref","unstructured":"Wang Y, Tong C, Lu Y, Wu Z, Guo Y, Liu Y et al. Characteristics of premanufacture CD8\u2009+\u2009T cells determine CAR-T Ef Fi Cacy in patients with diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(409).","DOI":"10.1038\/s41392-023-01659-2"},{"issue":"12","key":"7701_CR65","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2022","unstructured":"Oh DY, Fong L. Cytotoxic CD4\u2009+\u2009T cells in cancer: expanding the immune effector toolbox. Immunity. 2022;54(12):2701\u201311.","journal-title":"Immunity"},{"issue":"7","key":"7701_CR66","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4\u2009+\u2009CAR T-cell antitumor activity. Nat Cancer. 2023;4(7):968\u201383.","journal-title":"Nat Cancer"},{"key":"7701_CR67","doi-asserted-by":"crossref","unstructured":"Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lema\u00eetre F et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6(57).","DOI":"10.1126\/sciimmunol.abd4344"},{"issue":"1","key":"7701_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood.V96.1.195","volume":"96","author":"M Tateyam","year":"2000","unstructured":"Tateyam M, Oyaizu N, McCloskey TW, Than S, Pahwa S. CD4 T lymphocytes are primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell apoptosis via Fas\/FasL death signaling pathway. Blood. 2000;96(1):195\u2013202.","journal-title":"Blood"},{"issue":"7897","key":"7701_CR69","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MKA, et al. Decade-long leukaemia remissions with persistence of CD4\u2009+\u2009CAR T cells. Nature. 2022;602(7897):503\u20139.","journal-title":"Nature"},{"issue":"25","key":"7701_CR70","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan A, Zoine JT, Crawford JC, Vaidya A, Schattgen SA, Myers JA, et al. Engineering naturally occurring CD7\u2009\u2013\u2009T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684\u201396.","journal-title":"Blood"},{"issue":"5","key":"7701_CR71","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.4049\/jimmunol.170.5.2349","volume":"170","author":"EM Aandahl","year":"2003","unstructured":"Aandahl EM, Sandberg JK, Beckerman KP, Task\u00e9n K, Moretto WJ, Nixon DF. CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol. 2003;170(5):2349\u201355.","journal-title":"J Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07701-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07701-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07701-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:04:34Z","timestamp":1770771874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07701-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7701"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07701-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study was approved by the Institutional Animal Care and Use Committee of the University of Groningen. Patient material was obtained after informed consent and protocol approval by the Medical Ethical committee of the UMCG in accordance with the Declaration of Helsinki (protocol code NL43844.042.13, 6 January 2014).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}